PPARG and metabolic syndrome: We previously showed that the specific PPARα agonist fenofibrate, an FDA-approved drug used to treat dyslipidemia with minimal activity toward PPARγ (Kim et al., 2016; Rosenson, 2008), upregulated PPARα target genes in the DRG and rescued the impaired axon growth in mice lacking fatty acid synthase in SGC (Avraham et al., 2020).